Vilma P. Barcia MD, PhD, MSc· @DrVilmaPBarcia · X·· 3 天前评分70
正文 · 原文
👏 Huge congratulations to my friend @JHernando3 on presenting the GETNE-T2216/CABOTHYROID trial at #ESMO26!
Promising results with cabozantinib in advanced thyroid cancer: ORR 24%, DCR 89.7% and median PFS 16.1 months.
Great work by @GrupoGetne 🇪🇸! @Ja_Capdevila @OncoAlert
365 浏览 · 7 赞 · 7 转发 · 0 回复
来源：Vilma P. Barcia MD, PhD, MSc · x.com